HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

Abstract
The objective of this analysis was to describe the pharmacokinetic characteristics of anidulafungin in patients with serious fungal disease based on pharmacokinetic data collected during four recently completed or ongoing Phase II/III clinical studies. A total of 600 anidulafungin plasma samples from 225 patients across the four studies were available for analysis. Patients received daily intravenous infusions of 50, 75, or 100 mg anidulafungin, preceded by a loading dose that was twice the daily dose. The analysis population consisted of 129 patients with esophageal candidiasis, 87 with invasive candidiasis, 7 with invasive aspergillosis, and 2 with azole refractory mucosal candidiasis. A population analysis approach was used to develop a steady-state pharmacokinetic model for anidulafungin, assess the significance of possible covariates, and determine the amount of intersubject and random residual variability. A two-compartment model with first-order elimination provided the best fit to the data. The clearance of anidulafungin was influenced by weight and gender, and subjects in the invasive candidiasis study had a typical clearance that was approximately 30% higher than subjects from other studies. Weight was determined to be a predictor of the central volume of distribution. The covariates on clearance accounted for less than 20% of the intersubject variability and therefore are deemed to be of little clinical relevance. There was no evidence that the presence of rifampin or metabolic substrates, inhibitors, or inducers of cytochrome p450 influenced the clearance of anidulafungin. This indicates that dosing adjustments are not necessary when anidulafungin is administered in the presence of medications falling into these classifications.
AuthorsJames A Dowell, William Knebel, Tom Ludden, Marty Stogniew, David Krause, Tim Henkel
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 44 Issue 6 Pg. 590-8 (Jun 2004) ISSN: 0091-2700 [Print] England
PMID15145966 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Peptides, Cyclic
  • Anidulafungin
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anidulafungin
  • Antifungal Agents (blood, pharmacokinetics, therapeutic use)
  • Aspergillosis (drug therapy)
  • Candidiasis (drug therapy)
  • Drug Interactions
  • Echinocandins
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Models, Biological
  • Monte Carlo Method
  • Peptides, Cyclic (blood, pharmacokinetics, therapeutic use)
  • Racial Groups
  • Sex Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: